Re-mark
Fruquintinib (Elunate/Fruzaqla) is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor indicated for the treatment of previously treated metastatic colorectal cancer (mCRC). By selectively targeting VEGFR-1, VEGFR-2, and VEGFR-3, it helps inhibit tumor angiogenesis, a key process in cancer growth and progression. Fruquintinib is available in 1 mg and 5 mg capsule strengths, with dosing administered according to the approved prescribing information and continued based on clinical benefit and tolerability.
You may like
Dr. Chandan Chaudhari offers kidney stone treatment in Mumbai for patients suffering from severe kidney stone pain,…
kidney stone, Kidney Stone treatment
Material Science of Precision Cleaving: Preventing Fiber Burn-Back in High-Power Surgical Laser Operations
During…